Corrigendum to: The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Bloodstream Infections Treated With Vancomycin.

[This corrects the article DOI: 10.1093/ofid/ofz079.].

The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Bloodstream Infections Treated With Vancomycin.

Background: Data suggest that vancomycin + β-lactam combinations improve the clearance of methicillin-resistant (MRSA) bloodstream infections (BSIs). However, it is unclear which specific β-lactams confer benefit. This analysis evaluates the impact of concomitant empiric cefepime on outcomes of MRSA BSIs treated with vancomycin.

The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Bloodstream Infections Treated With Vancomycin.

Background: Data suggest that vancomycin + β-lactam combinations improve clearance of methicillin-resistant (MRSA) bloodstream infections (BSIs). However, it is unclear which specific β-lactams confer benefit. This analysis evaluates the impact of concomitant empiric cefepime on outcomes of MRSA BSIs treated with vancomycin.